Gene Therapy Market by Vector Type (Viral Vector and Non-viral Vector), Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), and Application (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases): Global Opportunity Analysis and Industry Forecast, 2019–2026
- ALL3476356
- 310 Pages
- December 2019
- Healthcare
Gene therapy is a technique that involves the delivery of nucleic acid polymers into a patient’s cells as a drug to treat diseases. It fixes a genetic problem at its source. The process involves modifying the protein either to change the genetic expression or to correct a mutation. The emergence of this technology meets the rise in needs for better diagnostics and targeted therapy tools. For instance, genetic engineering can be used to modify physical appearance, metabolism, physical capabilities, and mental abilities such as memory and intelligence. In addition, it is also used for infertility treatment. Gene therapy offers a ray of hope for patients, who either have no treatment options or show no benefits with drugs currently available. The ongoing success has strongly supported upcoming researches and has carved ways for enhancement of gene therapy.
Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells. Gene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of clinical trials investigating gene therapies is on an increase, despite the limited number of products that have successfully reached the market. In addition, benefits of gene therapy over conventional cancer therapies and increase in government support fuel the growth of the gene therapy market.
The gene therapy market is a widely expanding field in the pharmaceutical industry with new opportunities. This has piqued the interests of venture capitalists to explore this market and its commercial potential. Major factors that drive the growth of this market include high demands for DNA vaccines to treat genetic diseases, targeted drug delivery, and high incidence of genetic disorders. However, the stringent regulatory approval process for gene therapy and the high costs of gene therapy drugs are expected to hinder the growth of the market. On the contrary, increase in the pipeline developments for gene therapy market are expected to provide lucrative opportunity during the forecast period.
The global gene therapy market is segmented based on vector type, gene type, application, and geography. Based on vector type, it is categorized into viral vector and non-viral vector. Viral vector is further segmented into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Non-viral vector is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. Based on gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others. Based on application, the market is divided into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY MARKET BENEFITS FOR STAKEHOLDERS
• This report offers a detailed quantitative analysis of the current market trends from 2018 to 2026 to identify the prevailing opportunities.
• The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
• In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
• The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Vector Type
• Viral vector
o Retroviruses
o Lentiviruses
o Adenoviruses
o Adeno Associated Virus
o Herpes Simplex Virus
o Poxvirus
o Vaccinia Virus
o Others
• Non-viral vector
o Naked/Plasmid Vectors
o Gene Gun
o Electroporation
o Lipofection
o Others
By Gene Type
• Antigen
• Cytokine
• Tumor Suppressor
• Suicide
• Deficiency
• Growth factors
• Receptors
• Others
By Application
• Oncological Disorders
• Rare Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Infectious disease
• Other Diseases
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Spain
o Italy
o Rest of Europe
• Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
• LAMEA
o Brazil
o South Africa
o Saudi Arabia
o Rest of LAMEA
KEY PLAYERS PROFILED
• Adaptimmune Therapeutics Plc.
• Anchiano Therapeutics Ltd.
• Achieve Life Sciences, Inc.
• Adverum Biotechnologies, Inc.
• Abeona Therapeutics Inc.
• Applied Genetic Technologies Corporation
• Arbutus Biopharma Corporation,
• Audentes Therapeutics, Inc.
• AveXis, Inc.
• Bluebird Bio, Inc.
• Celgene Corporation
• CRISPR Therapeutics AG
• Editas Medicine, Inc.
• Editas Medicine, Inc.
• GlaxoSmithKline Plc.
• Intellia Therapeutics, Inc.
• Merck & Co., Inc.
• Novartis AG
• REGENXBIO Inc.
• Spark Therapeutics, Inc.
• Sangamo Therapeutics, Inc.
• Uniqure N. V.
Voyager Therapeutics, Inc
The other players of the gene therapy market include (companies not profiled in the report):
• Amgen
• Epeius Biotechnologies
• Sanofi
• Juno Therapeutics
• Advantagene
1.1. Report Description
1.2. Key Benefits
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Top Player Positioning, 2018
3.4. Porter’S Five Forces Analysis
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. High Investment For R&D Activities Pertaining To Gene Therapy
3.5.1.2. Increase In Prevalence of Cancer
3.5.1.3. Growth In Awareness Regarding Gene Therapy
3.5.2. Restraints
3.5.2.1. High Cost Associated With Gene Therapies
3.5.2.2. Unwanted Immune Responses
3.5.3. Opportunities
3.5.3.1. Untapped Potential For Emerging Markets
Chapter 4: Gene Therapy Market, By Vector Type
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Viral Vectors
4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Size And Forecast, By Type
4.2.4. Market Size And Forecast, By Country
4.2.5. Adenovirus
4.2.6. Lentivirus
4.2.7. Retrovirus
4.2.8. Adeno-Associated Virus
4.2.9. Herpes Simplex Virus
4.2.10. Poxvirus
4.2.11. Vaccinia Virus
4.2.12. Others
4.3. Non-Viral Techniques
4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Size And Forecast, By Type
4.3.4. Market Size And Forecast, By Country
4.3.5. Naked Plasmid Vector
4.3.6. Gene Gun
4.3.7. Electroporation
4.3.8. Lipofection
4.3.9. Others
Chapter 5: Gene Therapy Market, By Gene Type
5.1. Overview
5.1.1. Market Size And Forecast, Type
5.2. Antigen
5.2.1. Market Size And Forecast
5.2.2. Market Size And Forecast, By Country
5.3. Cytokine
5.3.1. Market Size And Forecast
5.3.2. Market Size And Forecast, By Country
5.4. Tumor Suppressor
5.4.1. Market Size And Forecast, By Region
5.4.2. Market Size And Forecast, By Country
5.5. Suicide Gene
5.5.1. Market Size And Forecast
5.5.2. Market Size And Forecast, By Country
5.6. Deficiency
5.6.1. Market Size And Forecast, By Region
5.6.2. Market Size And Forecast, By Country
5.7. Growth Factors
5.7.1. Market Size And Forecast, By Region
5.7.2. Market Size And Forecast, By Country
5.8. Receptors
5.8.1. Market Size And Forecast, By Region
5.8.2. Market Size And Forecast, By Country
5.9. Others
5.9.1. Market Size And Forecast, By Region
5.9.2. Market Size And Forecast, By Country
Chapter 6: Gene Therapy Market, By Application
6.1. Overview
6.1.1. Market Size And Forecast, By Application
6.2. Oncological Disorders
6.2.1. Market Size And Forecast, By Region
6.2.2. Market Size And Forecast, By Country
6.3. Rare Diseases
6.3.1. Market Size And Forecast, By Region
6.3.2. Market Size And Forecast, By Country
6.4. Cardiovascular Diseases
6.4.1. Market Size And Forecast, By Region
6.4.2. Market Size And Forecast, By Country
6.5. Neurological Disorders
6.5.1. Market Size And Forecast
6.5.2. Market Size And Forecast, By Country
6.6. Infectious Diseases
6.6.1. Market Size And Forecast, By Region
6.6.2. Market Size And Forecast, By Country
6.7. Other Diseases
6.7.1. Market Size And Forecast
6.7.2. Market Size And Forecast, By Country
Chapter 7: Gene Therapy Market, By Region
7.1. Overview
7.1.1. Market Size And Forecast
7.2. North America
7.2.1. Key Market Trends, Growth Factors, And Opportunities
7.2.2. Market Size And Forecast, By Country
7.2.3. Market Size And Forecast, By Vector Type
7.2.4. Market Size And Forecast, By Gene Type
7.2.5. Market Size And Forecast, By Application
7.2.5.1. U.S. Market Size And Forecast, By Vector Type
7.2.5.2. U.S. Market Size And Forecast, By Gene Type
7.2.5.3. U.S. Market Size And Forecast, By Application
7.2.5.4. Canada Market Size And Forecast, By Vector Type
7.2.5.5. Canada Market Size And Forecast, By Gene Type
7.2.5.6. Canada Market Size And Forecast, By Application
7.2.5.7. Mexico Market Size And Forecast, By Vector Type
7.2.5.8. Mexico Market Size And Forecast, By Gene Type
7.2.5.9. Mexico Market Size And Forecast, By Application
7.3. Europe
7.3.1. Key Market Trends, Growth Factors, And Opportunities
7.3.2. Market Size And Forecast, By Country
7.3.3. Market Size And Forecast, By Vector Type
7.3.4. Market Size And Forecast, By Gene Type
7.3.5. Market Size And Forecast, By Application
7.3.5.1. Germany Market Size And Forecast, By Vector Type
7.3.5.2. Germany Market Size And Forecast, By Gene Type
7.3.5.3. Germany Market Size And Forecast, By Application
7.3.5.4. France Market Size And Forecast, By Vector Type
7.3.5.5. France Market Size And Forecast, By Gene Type
7.3.5.6. France Market Size And Forecast, By Application
7.3.5.7. Uk Market Size And Forecast, By Vector Type
7.3.5.8. Uk Market Size And Forecast, By Gene Type
7.3.5.9. Uk Market Size And Forecast, By Application
7.3.5.10. Italy Market Size And Forecast, By Vector Type
7.3.5.11. Italy Market Size And Forecast, By Gene Type
7.3.5.12. Italy Market Size And Forecast, By Application
7.3.5.13. Spain Market Size And Forecast, By Vector Type
7.3.5.14. Spain Market Size And Forecast, By Gene Type
7.3.5.15. Spain Market Size And Forecast, By Application
7.3.5.16. Rest of Europe Market Size And Forecast, By Vector Type
7.3.5.17. Rest of Europe Market Size And Forecast, By Gene Type
7.3.5.18. Rest of Europe Market Size And Forecast, By Application
7.4. Asia-Pacific
7.4.1. Key Market Trends, Growth Factors, And Opportunities
7.4.2. Market Size And Forecast, By Country
7.4.3. Market Size And Forecast, By Vector Type
7.4.4. Market Size And Forecast, By Gene Type
7.4.5. Market Size And Forecast, By Application
7.4.5.1. Japan Market Size And Forecast, By Vector Type
7.4.5.2. Japan Market Size And Forecast, By Gene Type
7.4.5.3. Japan Market Size And Forecast, By Application
7.4.5.4. China Market Size And Forecast, By Vector Type
7.4.5.5. China Market Size And Forecast, By Gene Type
7.4.5.6. China Market Size And Forecast, By Application
7.4.5.7. India Market Size And Forecast, By Vector Type
7.4.5.8. India Market Size And Forecast, By Gene Type
7.4.5.9. India Market Size And Forecast, By Application
7.4.5.10. South Korea Market Size And Forecast, By Vector Type
7.4.5.11. South Korea Market Size And Forecast, By Gene Type
7.4.5.12. South Korea Market Size And Forecast, By Application
7.4.5.13. Rest of Asia-Pacific Market Size And Forecast, By Vector Type
7.4.5.14. Rest of Asia-Pacific Market Size And Forecast, By Gene Type
7.4.5.15. Rest of Asia-Pacific Market Size And Forecast, By Application
7.5. Lamea
7.5.1. Key Market Trends, Growth Factors, And Opportunities
7.5.2. Market Size And Forecast, By Country
7.5.3. Market Size And Forecast, By Vector Type
7.5.4. Market Size And Forecast, By Gene Type
7.5.5. Market Size And Forecast, By Application
7.5.5.1. Brazil Market Size And Forecast, By Vector Type
7.5.5.2. Brazil Market Size And Forecast, By Gene Type
7.5.5.3. Brazil Market Size And Forecast, By Application
7.5.5.4. South Africa Market Size And Forecast, By Vector Type
7.5.5.5. South Africa Market Size And Forecast, By Gene Type
7.5.5.6. South Africa Market Size And Forecast, By Application
7.5.5.7. Rest of Lamea Market Size And Forecast, By Vector Type
7.5.5.8. Rest of Lamea Market Size And Forecast, By Gene Type
7.5.5.9. Rest of Lamea Market Size And Forecast, By Application
Chapter 8: Company Profile
8.1. Adaptimmune Therapeutics Plc.
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.1.6. Key Strategic Moves And Developments
8.2. Anchiano Therapeutics Ltd.
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.3. Achieve Life Sciences, Inc.
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Key Strategic Moves And Developments
8.4. Adverum Biotechnologies, Inc.
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Key Strategic Moves And Developments
8.5. Abeona Therapeutics Inc.
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.5.6. Key Strategic Moves And Developments
8.6. Applied Genetic Technologies Corporation
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.6.6. Key Strategic Moves And Developments
8.7. Arbutus Biopharma Corporation
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Product Portfolio
8.7.4. Business Performance
8.7.5. Key Strategic Moves And Developments
8.8. Audentes Therapeutics Inc.
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Product Portfolio
8.8.4. Key Strategic Moves And Developments
8.9. Avexis Inc.
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Product Portfolio
8.9.4. Key Strategic Moves And Developments
8.10. Bluebird Bio, Inc.
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
8.10.6. Key Strategic Moves And Developments
8.11. Celgene Corporation
8.11.1. Company Overview
8.11.2. Company Snapshot
8.11.3. Operating Business Segments
8.11.4. Product Portfolio
8.11.5. Business Performance
8.11.6. Key Strategic Moves And Developments
8.12. Crispr Therapeutics Ag
8.12.1. Company Overview
8.12.2. Company Snapshot
8.12.3. Product Portfolio
8.12.4. Business Performance
8.12.5. Key Strategic Moves And Developments
8.13. Editas Medicine, Inc.
8.13.1. Company Overview
8.13.2. Company Snapshot
8.13.3. Operating Business Segments
8.13.4. Product Portfolio
8.13.5. Business Performance
8.13.6. Key Strategic Moves And Developments
8.14. Gilead Sciences, Inc.
8.14.1. Company Overview
8.14.2. Company Snapshot
8.14.3. Operating Business Segments
8.14.4. Product Portfolio
8.14.5. Business Performance
8.14.6. Key Strategic Moves And Developments
8.15. Glaxosmithkline Plc
8.15.1. Company Overview
8.15.2. Company Snapshot
8.15.3. Operating Business Segments
8.15.4. Product Portfolio
8.15.5. Business Performance
8.15.6. Key Strategic Moves And Developments
8.16. Intellia Therapeutics Inc.
8.16.1. Company Overview
8.16.2. Company Snapshot
8.16.3. Operating Business Segments
8.16.4. Product Portfolio
8.16.5. Business Performance
8.16.6. Key Strategic Moves And Developments
8.17. Merck & Co., Inc.
8.17.1. Company Overview
8.17.2. Company Snapshot
8.17.3. Operating Business Segments
8.17.4. Product Portfolio
8.17.5. Business Performance
8.17.6. Key Strategic Moves And Developments
8.18. Novartis Ag
8.18.1. Company Overview
8.18.2. Company Snapshot
8.18.3. Operating Business Segments
8.18.4. Product Portfolio
8.18.5. Business Performance
8.18.6. Key Strategic Moves And Developments
8.19. Regenxbio, Inc.
8.19.1. Company Overview
8.19.2. Company Snapshot
8.19.3. Product Portfolio
8.19.4. Business Performance
8.19.5. Key Strategic Moves And Developments
8.20. Spark Therapeutics, Inc.
8.20.1. Company Overview
8.20.2. Company Snapshot
8.20.3. Operating Business Segments
8.20.4. Product Portfolio
8.20.5. Business Performance
8.20.6. Key Strategic Moves And Developments
8.21. Sangamo Therapeutics, Inc.
8.21.1. Company Overview
8.21.2. Company Snapshot
8.21.3. Operating Business Segments
8.21.4. Product Portfolio
8.21.5. Business Performance
8.21.6. Key Strategic Moves And Developments
8.22. Uniqure N. V.
8.22.1. Company Overview
8.22.2. Company Snapshot
8.22.3. Operation Segments
8.22.4. Product Portfolio
8.22.5. Business Performance
8.22.6. Key Strategic Moves And Developments
8.23. Voyager Therapeutics, Inc.
8.23.1. Company Overview
8.23.2. Company Snapshot
8.23.3. Operating Business Segments
8.23.4. Product Portfolio
8.23.5. Business Performance
8.23.6. Key Strategic Moves And Developments
Table 01. Late-Stage Clinical Data Events of Gene Therpy
Table 02. Gene Therapy Pipeline Volume, Preclinical Through Pre-Registration Phase, 1995–2018
Table 03. Global Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 04. Global Gene Therapy Market For Viral Vectors, By Region, 2018–2026 ($Million)
Table 05. Global Gene Therapy Market For Viral Vectors, By Type, 2018–2026 ($Million)
Table 06. Gene Therapy Market For Non-Viral Vectors, By Region, 2018–2026 ($Million)
Table 07. Global Gene Therapy Market For Non-Viral Vectors, By Type, 2018–2026 ($Million)
Table 08. Global Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 09. Antigen Gene Therapy Market, By Region, 2018–2026 ($Million)
Table 10. Cytokine Gene Therapy Market, By Region, 2018–2026 ($Million)
Table 11. Tumor Suppressor Gene Therapy Market, By Region, 2018–2026 ($Million)
Table 12. Suicide Gene Therapy Market, By Region, 2018–2026 ($Million)
Table 13. Deficiency Gene Therapy Market, By Region, 2018–2026 ($Million)
Table 14. Growth Factors Gene Therapy Market, By Region, 2018–2026 ($Million)
Table 15. Receptors Gene Therapy Market, By Region, 2018–2026 ($Million)
Table 16. Gene Therapy Market For Other Gene Types, By Region, 2018–2026 ($Million)
Table 17. Global Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 18. Gene Therapy Market For Oncological Disorders, By Region, 2018–2026 ($Million)
Table 19. Gene Therapy Market For Rare Diseases, By Region, 2018–2026 ($Million)
Table 20. Gene Therapy Market For Cardiovascular Diseases, By Region, 2018–2026 ($Million)
Table 21. Gene Therapy Market For Neurological Disorders, By Region, 2018–2026 ($Million)
Table 22. Gene Therapy Market For Infectious Diseases, By Region, 2018–2026 ($Million)
Table 23. Gene Therapy Market For Other Diseases, By Region, 2018–2026 ($Million)
Table 24. Gene Therapy Market, By Region, 2018-2026 ($Million)
Table 25. North America Gene Therapy Market, By Country, 2018–2026 ($Million)
Table 26. North America Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 27. North America Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 28. North America Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 29. U.S. Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 30. U.S. Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 31. U.S. Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 32. Canada Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 33. Canada Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 34. Canada Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 35. Mexico Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 36. Mexico Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 37. Mexico Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 38. Europe Gene Therapy Market, By Country, 2018–2026 ($Million)
Table 39. Europe Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 40. Europe Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 41. Europe Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 42. Germany Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 43. Germany Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 44. Germany Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 45. France Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 46. France Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 47. France Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 48. Uk Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 49. Uk Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 50. Uk Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 51. Italy Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 52. Italy Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 53. Italy Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 54. Spain Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 55. Spain Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 56. Spain Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 57. Rest of Europe Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 58. Rest of Europe Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 59. Rest of Europe Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 60. Asia-Pacific Gene Therapy Market, By Country, 2018–2026 ($Million)
Table 61. Asia-Pacific Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 62. Asia-Pacific Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 63. Asia-Pacific Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 64. Japan Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 65. Japan Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 66. Japan Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 67. China Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 68. China Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 69. China Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 70. India Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 71. India Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 72. India Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 73. South Korea Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 74. South Korea Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 75. South Korea Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 76. Rest of Asia-Pacific Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 77. Rest of Asia-Pacific Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 78. Rest of Asia-Pacific Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 79. Lamea Gene Therapy Market, By Country, 2018–2026 ($Million)
Table 80. Lamea Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 81. Lamea Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 82. Lamea Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 83. Brazil Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 84. Brazil Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 85. Brazil Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 86. South Africa Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 87. South Africa Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 88. South Africa Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 89. Rest of Lamea Gene Therapy Market, By Vector Type, 2018–2026 ($Million)
Table 90. Rest of Lamea Gene Therapy Market, By Gene Type, 2018–2026 ($Million)
Table 91. Rest of Lamea Gene Therapy Market, By Application, 2018–2026 ($Million)
Table 92. Adaptimmune: Company Snapshot
Table 93. Adaptimmune: Business Unit
Table 94. Adaptimmune.: Product Portfolio
Table 95. Anchiano Therapeutics: Company Snapshot
Table 96. Anchiano Therapeutics: Product Category
Table 97. Anchiano Therapeutics: Product Portfolio
Table 98. Achieve Life Sciences.: Company Snapshot
Table 99. Achieve Life Sciences.: Operating Segments
Table 100. Achieve Life Sciences: Product Portfolio
Table 101. Adverum Biotechnologies, Inc.: Company Snapshot
Table 102. Adverum Biotechnologies, Inc.: Product Category
Table 103. Adverum Biotechnologies, Inc.: Product Portfolio
Table 104. Abeona Therapeutics Inc.: Company Snapshot
Table 105. Abeona Therapeutics Inc.: Product Category
Table 106. Abeona Therapeutics Inc.: Product Portfolio
Table 107. Applied Genetic Technologies Corporation: Company Snapshot
Table 108. Applied Genetic Technologies Corporation: Operating Segments
Table 109. Applied Genetic Technologies Corporation: Product Portfolio
Table 110. Arbutus: Company Snapshot
Table 111. Arbutus: Product Portfolio
Table 112. Audentes: Company Snapshot
Table 113. Audentes: Product Portfolio
Table 114. Avexis: Company Snapshot
Table 115. Avexis: Product Portfolio
Table 116. Bluebird Bio : Company Snapshot
Table 117. Bluebird Bio: Product Category
Table 118. Bluebird Bio.: Product Portfolio
Table 119. Celgene: Company Snapshot
Table 120. Celgene: Operating Segments
Table 121. Celgene: Product Portfolio
Table 122. Crispr: Company Snapshot
Table 123. Crispr: Product Portfolio
Table 124. Editas.: Company Snapshot
Table 125. Editas: Product Portfolio
Table 126. Gilead: Company Snapshot
Table 127. Gilead: Operating Segments
Table 128. Gilead: Product Portfolio
Table 129. Gsk.: Company Snapshot
Table 130. Gsk: Operating Segments
Table 131. Gsk: Product Portfolio
Table 132. Intellia: Company Snapshot
Table 133. Intellia: Product Portfolio
Table 134. Merck: Company Snapshot
Table 135. Merck: Operating Segments
Table 136. Merck.: Product Portfolio
Table 137. Novartis: Company Snapshot
Table 138. Novartis: Operating Division
Table 139. Novartis: Product Portfolio
Table 140. Regenxbio: Company Snapshot
Table 141. Regenxbio: Product Portfolio
Table 142. Spark Therapeutics: Company Snapshot
Table 143. Spark Therapeutics, Inc.: Product Category
Table 144. Spark Therapeutics, Inc.: Product Portfolio
Table 145. Sangamo Therapeutics: Company Snapshot
Table 146. Sangamo Therapeutics: Operating Business Segments
Table 147. Sangamo Therapeutics: Product Portfolio
Table 148. Uniqure: Company Snapshot
Table 149. Uniqure: Product Business Segment
Table 150. Uniqure.: Product Portfolio
Table 151. Voyager.: Company Snapshot
Table 152. Voyager : Product Business Segments
Table 153. Voyager.: Product Portfolio
Similar Reports
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
- Publish Date: February 26, 2018
- $5370
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
- Publish Date: May 29, 2018
- $5370
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...
- Publish Date: May 1, 2016
- $5370
